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A B S T R A C T
Purpose: Serotonin is a key regulatory neurotransmitter in the CNS which plays an important role in seizure
through different receptors, especially the 5HT1A subtype. The role of sertraline through the 5HT1A receptor
and nitric oxide interaction on the PTZ-induced seizure threshold was investigated in this study.
Method: In this study, 70 white male mice were randomly divided into 10 groups including intact control,
sham-control and eight experimental groups which received sertraline, 8-OH-DPAT, WAY100635,
WAY100635 + sertraline, WAY100635 + 8-OH-DPAT, L-NAME, L-NAME + sertraline and L-NAME + 8-OH-DPAT.
After 14 days of treatment in different groups, the PTZ-induced seizure threshold was assessed and the
measurement of nitric oxide metabolites in the brain tissue was done with the Greiss method.
Results: The seizure threshold was significantly increased in the sertraline and 8OH-DPAT receiving groups
compared to the sham group (P 0.001). In the presence of WAY100635, the effect of both sertraline and
8-OH-DPAT in raising the seizure threshold was more prominent (P 0.001) but on the other hand, in the
presence of L-NAME, an increase in the anticonvulsant effect of 8-OH-DPAT was observed, while L-NAME
alone had no effect on the seizure threshold (P 0.001). The NOX concentration was significantly decreased in
the 8-OH-DPAT_treated group (P 0.01), while the WAY100657 reversed it and the combination of 8-OH-
DPAT with L-NAME reduced the NOX levels (P 0.001).
Conclusions: These findings support the anticonvulsant effect of SSRIs and selective 5HT1A receptors,
although serotonin receptors other than 5HT1A subtype may be involved and also it is probable that some
anticonvulsant effects of the sertraline and 8-OH-DPAT are through the modulation of nitrergic system.
© 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Serotonin or 5-hydroxytryptamine is a monoamine neurotrans-
mitter derived from hydroxylation and decarboxylation of
L-tryptophan [1–3] and can regulate various physiological and
behavioral processes [4,5]. Each type of disturbance in the synthesis,
metabolism or reuptake of serotonin may lead to neurological
disorders such as migraine, Alzheimer's disease, depression and
seizure [6–8]. Serotonin has seven families of receptors (5HT1 to
5HT7) that may be involved in different types of seizures [9,10].
Serotonergic projections which are extensive in the anterior brain
and brain stem structures [9].
Among various subtypes of serotonin receptors (5HT1 to 5HT7),
the 5HT1A receptor plays an important role in seizures [11]. In the
mammalian brain, the 5HT1A receptor has pre- and post-synaptic* Corresponding author.
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1059-1311/© 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reservdistribution [12]. Activation of the 5HT1A autoreceptor diminishes
the activity of serotonergic neurons and thereby decreases the
release of serotonin. In contrast, the activity of the postsynaptic
5HT1A receptors mimics the effects of the serotonin release and
facilitates serotonin transmission [13,14]. Unfortunately in acute
seizures with a natural hippocampus, the effect of the 5HT1A
receptor is still controversial [15]. In different seizure models, the
5HT1A receptor can have exerts anticonvulsant [16,17] and procon-
vulsant effects [18] or even it can have a neutral effect [19,20] on
seizure.
Nitric oxide (NO) is synthesized from L-arginine by the nitric
oxide synthase (NOS) [21] and plays an important role in the normal
action of the brain [22]. Although it has shown its anticonvulsant or
proconvulsant properties in different seizure models but its role in
seizure is not completely clear [23].
Recently, the interaction between the 5-HT receptor subtypes
and NO has been proposed [21]. Some selective serotonin reuptake
inhibitors (SSRIs) such as paroxetine act as an NOS inhibitor [24]. On
the other hand, some NOS inhibitors such as L-NG-Nitroarginineed.
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effect of SSRIs. The 5HT1A agonists such as 8-OH-DPAT downregulate
nNOS expression and leads to a decrease in NO, an effect which is
blocked by application of the 5- HT1A receptor antagonists. These
findings suggest that NO may be a downstream signaling molecule
of 5-HT [25]. A model of the 5-HT1A receptor-nNOS-CREB pathway
has been proposed in some studies [24,25]. In the present study, we
examined the effect of chronic administration of sertraline and 8-
OH-DPAT on the PTZ-induced clonic seizures threshold in male mice.
Regarding the functional interactions of 5HT with NO signaling
pathway and the fact that both sertraline and 8-OH-DPAT are the
5HT1A receptor agonist, we further investigated the possible
involvement of NO in the modulatory effect of these compounds
on the seizure susceptibility by using L-NAME.
2. Method
All experiments were performed in accordance with the guide for
the Care and Use of Laboratory Animals (National Institutes of
Health Publication No. 85-23, revised 1985). They were also
approved by the Research and Ethics Committee of Kashan
University of Medical Sciences, Kashan, Iran. White male mice (25–
30 g) were bred in the animal house of Physiology Research Center,
Kashan University of Medical Sciences. They were housed in the
standard polypropylene cages under standard temperature (25 degC)
and humidity (%50–60) with a 12 h light and 12 h dark cycle. They
were fed standard mouse food with ad libitum access to water.
Animals were divided randomly into ten groups (n = 7 in each group)
including intact control, sham-control and eight experimental
groups which received sertraline, 8-OH-DPAT, WAY100635,
WAY100635 + sertraline, WAY100635 + 8-OH-DPAT, L-NAME, L-
NAME + sertraline and L-NAME + 8-OH-DPAT.
2.1. Chemicals and drugs
The drugs used were PTZ, sertraline, 8-OH-DPAT, WAY100635 and
L-NAME. All the above_mentioned drugs except sertraline were
purchased from Sigma (USA). Sertraline was purchased from
Darupakhsh (Tehran/Iran).Fig. 1. The effect of chronic pre-treatment with WAY-100635 in combination with 8-OH
significantly increased in treatment with 8-OH-DPAT or sertraline. This effect also was 
sertraline. ***P 0.001 compared to vehicle. P 0.001 compared to 8-OH-DPAT group. {{{ P
group.2.2. Procedure
PTZ(0.5% solution) was prepared in 0.9% saline and administered
as intravenous infusion. In addition, sertraline was prepared at
carboxymethylcellulose(CMC, 0.5%) as a solvent agent and adminis-
tered orally by gavage for 14 days.
Other drugs were dissolved in normal saline solution at desired
concentration and administered intraperitoneally (IP), in a volume of
10 ml/kg of body weight.
The doses of sertraline, 8-OH-DPAT, WAY100635 and L-NAME
were chosen based on the previous studies and pilot experiments.
WAY100635 was injected 30 min before the administration of
sertraline or 8-OH-DPAT.
2.3. Seizure induction
PTZ was dissolved in heparinized sterile saline (0.9%) to prepare a
fresh solution with a concentration of 5 mg/ml before an intravenous
(IV) infusion. The dose and infusion rate of the administered PTZ was
5 mg/ml and 0.5 ml/min, respectively [26]. Before testing, each
mouse was weighed and placed in a clear acrylic plastic restrainer
and then its tail was immersed in a warm water bath (40–45 degC)
for 1 min to dilate the tail veins. A dental carpule (30 G) connected by
a polyethylene tube (No. 10) to a 10 ml syringe prefilled with
heparinized PTZ solution was used. The needle was inserted into the
mid length of the lateral tail vein and during the infusion period, the
animal could move freely with the aid of attached canula. Each
animal was observed throughout the infusion period and the
duration time between the start of infusion and onset of clonic
seizures was recorded in seconds and converted to the threshold
convulsant dosage by the following formula [27]:
Seizure Threshold
¼ Concentration ðmg=mlÞ  Infusion Rate ðml=minÞ  Time ðsÞ  1000
Weight ðgÞ  60-DPAT or sertraline treatment on the seizure threshold. The seizure threshold was
potentiated with pre-treatment by WAY100635 in combination with 8-OH-DPAT or
 < 0.001 compared to sertraline group. ### P < 0.001 compared to WAY100635
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The assay described by Miranda et al. [28] was used to reduce
nitrate to nitrite by vanadium (III) chloride, followed by the
spectrophotometric analysis of total nitrite using Greiss reagent.
For the measurement of nitric oxide metabolites in the brain tissue
samples, 1 gram of brain tissue was homogenized in 10 ml of Tris Hcl
50 M, containing 0.1 mM EDTA and the homogenized suspension was
deproteinized by trichloroacetic acid (10%) to reduce turbidity.
Experiments were performed at room temperature, as noted. A
nitrate standard solution (100 ml) was serially diluted (from 20 to
100 M) in a 96-well microplate. First, plate loaded with samples
(100 l) and VCl3 (100 l), then sulfanilamide (50 l) and NEDD (50 l)
were added to each well and at last diluting medium was used to
determine blank values. It should be noted that the absorbance at
540 nm was measured by using a plate reader following the
incubation (45 min) [29].
2.5. Statistical analysis
All results were expressed as mean values SEM. Statistical
analysis of the results was done by one-way ANOVA for the seizure
thresholds followed by Tukey’s test for multiple comparisons.
Differences were considered significant if the P value were less than
0.05.
3. Results
Fig. 1 illustrates the effects of 14 days sertraline (10 mg/kg) or
8-OH-DPAT (1 mg/kg) administration on the PTZ-induced seizure
threshold. The clonic seizure threshold was increased significantly in
both sertraline and 8-OH-DPAT treated groups compared to the
vehicle (P 0.001). WAY100635, the specific 5HT1A receptor antago-
nist (0.3 mg/kg, i.p) alone did not alter the PTZ-induced clonic
seizure threshold. Unexpectedly, the combination of WAY100635
(0.3 mg/kg, i.p) with 8-OH-DPAT or sertraline, potentiated the
anticonvulsant effect of both drugs.
Fig. 2 illustrates the effects of 14 days L-NAME administration
(50 mg/kg) alone and in combination with sertraline (30 mg/kg) or
8-OH-DPAT (1 mg/kg). Sub-effective dose of L-NAME (50 mg/kg)
failed to show anticonvulsant activity. The co-administration of
L-NAME (50 mg/kg) with 8-OH-DPAT (1 mg/kg) significantly
increased the PTZ-induced seizure threshold, while theFig. 2. The effect of chronic pre-treatment with L-NAME alone and in combination of 8-OH
increased in pre-treatment with L-NAME in combination with 8-OH-DPAT but this effect wa
with sertraline. ***P 0.001 compared to L-NAME.co-administration of L-NAME (50 mg/kg) with sertraline (10 mg/kg)
had no effect on the seizure threshold.
Fig. 3 shows the brain tissues concentration of NOx in the
L-NAME treated groups. L-NAME at sub-effective concentration
(50 mg/kg) significantly decreased the NOx concentration compared
to the sham control group (p 0.01).
The brain tissues concentrations of NOx in 8-OH-DPAT treated
group was significantly lower than sham group and the
co-administration of sub-effective of L-NAME(50 mg/kg) with 8OH-
DPAT(1 mg/kg) further decreased NOx concentration. Sertraline
(10 mg/kg) alone or in combination with sub-effective concentration
of L-NAME (50 mg/kg) had no significant effect on NOx
concentration.
4. Discussion
In the present study, we investigated the effect of sertraline
(a SSRI inhibitor) and 8-OH-DPAT (a specific 5HT1A receptor
antagonist) on the PTZ-induced clonic seizure threshold. The results
showed that both sertraline and 8OH-DPAT significantly increased
the PTZ-induced clonic seizure threshold in mice.
Some studies indicate that serotonin has a protective effect
against epilepsy in the central nervous system and some SSRIs have
anticonvulsant effect [30]. Loscher showed that the stimulation of
5HT1A receptor with SSRIs had protective effects against seizures
[31]. Although some studies have shown that the anticonvulsant
effect of SSRIs is not solely mediated through the 5HT1A receptor
[32,33].
SSRI family has been found to possess antiepileptic properties in
human and animal models of epilepsy [34].
The primary effect of SSRIs is increasing 5HT in the synaptic cleft.
The results of animal studies show that 5-HT plays an important role
in the neural excitability, epileptogenesis, and seizure propagation
[35,36]. Among the SSRIs, sertraline was selected, because it has the
lowest reported seizure occurrence [37] and can be safely used in
the vast majority of epileptic patients [38].
In accordance with the sertraline increased the PTZ-induced
seizure threshold in this study, studies showing that agents such as
SSRIs have antiepileptic effect through the increase of extracellular
5-HT [11,39], just like sertraline, 8OH-DPAT increased the
PTZ-induced seizure threshold. The activation of 5HT1A receptors
inhibits adenylyl cyclase and decreases cAMP production. It also-DPAT or sertraline on the seizure threshold. The seizure threshold was significantly
s not observed with pre-treatment with L-NAME alone or with L-NAME in combination
Fig. 3. The effect of the chronic L-NAME with 8-OH-DPAT or sertraline treatment on NOX concentration. NOX concentration was significantly reduced in pre-treatment with L-
NAME in combination of 8-OH-DPAT and also this effect was observed during the treatment with L-NAME or 8-OH-DPAT alone. ***P 0.001 and **P 0.01 compared to vehicle group.
{{{ P < 0.001 compared to 8-OH-DPAT. ^^^ P < 0.001 compared to L-NAME. ### P < 0.001 compared to sertraline.
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generally believed that the 5HT1A activation increases the seizure
threshold in most of the animal models, some studies have
demonstrated that the 5TH1A agonists such as 8OH-DPAT decrease
the seizure threshold [41,42]. However, our results confirm the
findings that show the 5HT1A have anticonvulsant effect. Of course, it
must be noted that 8OH-DPAT has also affinity for other 5HT7
receptors [19].
WAY100635 (N-[4-2-methoxyphenyl)-1-piperazinyl]-N-(2-pyri-
dinyl)cyclo hexanecarboxamide alone had no effect on the seizure
threshold. Interestingly, the co-administration of sertraline or
8-OH-DPAT with WAY-100635 further increased the seizure
threshold. Similarly, Manuel-Apolinar et al. [39] reported that
8OH-DPAT increased cAMP in cortex and hippocampus and the
co-administration of WAY 100635 with 8OH-DPAT produced
higher levels of cAMP in these areas. They proposed a possible
link among the 5HT1A and 5HT7 receptors, because 8OH-DPAT had
affinity to both receptors [39]. Since WAY 100635 is highly
selective antagonist for the 5-HT1A receptor [6], it is likely that
anticonvulsant effect of sertraline and 8OH-DPAT has been
potentiated by the involvement of 5HT7 receptor. These data
suggest possible interplay between the 5-HT1A and 5-HT7
receptors during anticonvulsant drug action.
In the case of 5HT7, both proconvulsant and anticonvulsant
effects have been reported [43–45]. According to the study of
Mirski et al., the 5HT1/5A/7 agonist, 5-CT, increased the PTZ-induced
seizure threshold in rats [46] and also in 5HT7 knockout mice, the
threshold of PTZ, NMDA, cocaine and electroshock- induced
seizures were decreased [44]. Thus, it is likely that the antic-
onvulsant effect of sertraline and 8OH-DPAT in the presence of
WAY100635 has been potentiated through the modulation of 5HT1A
autoreceptors.
The effect of SSRIs partly depends on the 5-HT1A auto-receptor
functions. The 5-HT7 receptors can also be involved in the
therapeutic effects of these drugs. For example, SSRIs induced
c-Fos expression in rats. The effect is like the 5-HT7 receptor
activation. Moreover, chronic treatment with SSRIs decreased the
5-HT7 receptor binding [47].
The 5HT1A receptor is widely known as an autoreceptor [40] that
reduces the release of serotonin during the treatment with SSRI, andleads to a delay in the onset of therapeutic effects of SSRI. The
combination of 5HT1A receptor antagonist with the SSRI by
inhibiting the autoreceptor, maximizes the serotonin levels and
strengthens the effect of SSRI [15]. On the other hand, a study has
shown that by a dose between 1.0 to 3.0 mg/kg of WAY100635, the
somatodendritic 5HT1A receptors have been blocked [40,42]. In the
present study, this assumption may be made that the 5HT1A
antagonist (WAY100635) with preferential inhibition of autorecep-
tor, enhances the effect of sertraline through postsynaptic receptors.
Then, increase in the amount of extracellular serotonin leads to the
increase in the seizure threshold and augment the anticonvulsant
effect.
NO is a free radical with signaling functions in the CNS and is
mainly produced by neuronal nitric oxide synthase (nNOS) [21].
Based on previous studies, NO has both proconvulsant and antic-
onvulsant properties [23]. The role of nitrergic system in the central
effects of 5HT agonists and SSRIs has been previously described. For
example, nNOS-derived NO has been reported to induce antide-
pressant and anxiolytic effects [48–50]. In addition, the effects of NO
on locomotor activity in the dorsal raphe nucleus is mediated
through the 5HT1A receptors [51].
In the case of epilepsy, low doses of citalopram had antic-
onvulsant effect through the 5HT3 receptors and the combination of
L-NAME or 7-NI with citalopram augmented this effect [52].
In the present study, 14 days pretreatment with 8OH-DPAT,
unlike sertraline, was accompanied by lower levels of NOx in brain
tissues in comparison with sham-operated rats.
According to previous studies, the stimulation of 5HT1A receptor
led to downregulation of nNOS expression in the hippocampus. In
addition, the knock-out of nNOS gene or use of 7-NI as a selective
nNOS inhibitor, abolished anxiolytic effects of 8OH-DPAT or
fluoxetine [25]. The authors suggested that nNOS was important in
normal brain 5-HT function, especially in the 5HT1A post synaptic
receptor function [53]. Considering that 8OH-DPAT is a selective
agonist of the 5HT1A receptor, decreased level of NOx in 8OH-DPAT-
treated rats is conceivable. WAY100635 abolished the effect of 8OH-
DPAT which confirmed the involvement of 5HT1A receptor activation.
In addition, the combination of sub-effective doses of L-NAME and
sertraline further decreased NOx levels and the concomitant
increase of seizure threshold. Thus, it seems that interaction
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responsible for the anticonvulsant effect of 8OH-DPAT.
Taking into account the inhibitory effect of 5HT1A receptor
agonists on nNOS, it is probable that combination of L-NAME with
8OH-DPAT augment the anticonvulsant effect of these two 5HT1A
receptor agonist. Although there are some reports that SSRIs
diminish NO levels in the CNS, our results showed that sertraline
did not significantly change NOx levels. Furthermore, Bahremand
et al. have reported that combination of L-arginine with high doses of
citalopram was mediated by 5HT3 receptor through increased
activation of NOS [54]. In proof of this claim, the combination of
sertraline with non-effective dose of L-NAME did not significantly
change the seizure threshold or NOx levels.
5. Conclusions
During the last decade, many studies have indicated the
important role of serotonin in seizure. According to the presented
data, it seems that sertraline and 8OH-DPAT have anticonvulsant
effect through the 5HT1A receptors, although serotonin receptors
other than 5HT1A subtype may be involved. Furthermore, it is
probable that some anticonvulsant effect of sertraline and 8OH-
DPAT are through the modulation of nitrergic system.
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